Monte Rosa Therapeutics develops molecular glue degraders (GLUE) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Monte Rosa Therapeutics develops molecular glue degraders (GLUE) right now is Novartis partnerships: Two Novartis agreements validate the platform and fund it: a 2024 license for VAV1-directed MRT-6160 (about $150M upfront plus up to roughly $2.1B in milestones) and a broader 2025 immunology and inflammation deal (about $120M upfront plus up to roughly $5.4B in milestones). Revenue (TTM) is ~$43M. If that keeps playing out, the setup is favourable; the risk to it is monte Rosa is pre-product and unprofitable, so it depends on clinical success and continued financing. No one can predict where GLUE trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Monte Rosa Therapeutics develops molecular glue degraders (GLUE) higher?
1. Novartis partnerships
Two Novartis agreements validate the platform and fund it: a 2024 license for VAV1-directed MRT-6160 (about $150M upfront plus up to roughly $2.1B in milestones) and a broader 2025 immunology and inflammation deal (about $120M upfront plus up to roughly $5.4B in milestones). These deals supply non-dilutive cash and milestone upside if partnered programs advance.
2. MRT-8102 in inflammation and cardiovascular disease
The NEK7-directed degrader MRT-8102 showed profound CRP reductions in an interim Phase 1 readout in January 2026 (about an 85% CRP drop after four weeks in elevated-CVD-risk subjects). A further GFORCE-1 readout in atherosclerotic cardiovascular disease is anticipated in the second half of 2026, a potentially large market catalyst.
3. QuEEN platform breadth
The QuEEN discovery engine is designed to generate new molecular glue degraders against historically undruggable targets. A productive platform can seed additional wholly owned programs and further partnering deals, spreading risk across multiple shots rather than a single asset.
4. Oncology optionality with MRT-2359
MRT-2359 targets MYC-driven cancers, including a planned signal-confirming study in AR-mutant castration-resistant prostate cancer. It adds an oncology dimension to a pipeline otherwise weighted toward immunology and inflammation.
What could weigh on GLUE?
Monte Rosa is pre-product and unprofitable, so it depends on clinical success and continued financing. Molecular glue degraders remain a relatively young modality, and early positive biomarker data (such as CRP reductions) do not guarantee later-stage clinical or regulatory success. Much of the company's headline value comes from Novartis milestone potential that is contingent and may never be earned. The stock is volatile and can move sharply on single data points, and future capital raises could dilute shareholders. Competition in targeted protein degradation is intensifying across both large pharma and specialized biotechs.
Where GLUE trades today
A forecast starts from where the stock actually is. These are GLUE's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for GLUE as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a GLUE forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the GLUE guide and whether GLUE is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the GLUE outlook
The bottom line: what is driving Monte Rosa Therapeutics develops molecular glue degraders (GLUE) is Novartis partnerships, with revenue (ttm) at ~$43M. If that keeps playing out the setup is favourable; the risk is monte Rosa is pre-product and unprofitable, so it depends on clinical success and continued financing. No one can predict the price, so treat any GLUE forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around GLUE with Walnut
Use Monte Rosa Therapeutics develops molecular glue degraders as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Monte Rosa Therapeutics develops molecular glue degraders (GLUE)?
+
No one can reliably predict where GLUE will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Monte Rosa Therapeutics develops molecular glue degraders higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive GLUE higher?
+
The main growth drivers are Novartis partnerships; MRT-8102 in inflammation and cardiovascular disease; QuEEN platform breadth. Whether they play out is the real question, not a guaranteed path.
What are the risks to GLUE?
+
Monte Rosa is pre-product and unprofitable, so it depends on clinical success and continued financing. Molecular glue degraders remain a relatively young modality, and early positive biomarker data (such as CRP reductions) do not guarantee later-stage clinical or regulatory success. Much of the company's headline value comes from Novartis milestone potential that is contingent and may never be earned. The stock is volatile and can move sharply on single data points, and future capital raises could dilute shareholders. Competition in targeted protein degradation is intensifying across both large pharma and specialized biotechs.
Will GLUE stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Monte Rosa Therapeutics develops molecular glue degraders's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is GLUE a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the GLUE "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.